American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines

Thomas J Smith, Nancy E. Davidson, David V. Schapira, Eva Grunfeld, Hyman B. Muss, Victor G. Vogel, Mark R. Somerfield

Research output: Contribution to journalArticle

Abstract

Objective: To determine an effective, evidence-based, postoperative surveillance strategy for the detection and treatment of recurrent breast cancer. Tests are recommended only if they have an impact on the outcomes specified by American Society of Clinical Oncology (ASCO) for clinical practice guidelines. Potential Interventlon: All tests described in the literature for postoperative monitoring were considered. In addition, the data were critically evaluated to determine the optimal frequency of monitoring. Outcome: Outcomes of interest include overall and disease-free survival, quality of life, toxicity reduction, and secondarily cost- effectiveness. Evidence: A search was performed to determine all relevant articles published over the past 20 years on the efficacy of surveillance testing for breast cancer recurrence. These publications comprised both retrospective and prospective studies. Values: Levels of evidence and guideline grades were rated by a standard process. More weight was given to studies that tested a hypothesis directly relating testing to one of the primary outcomes in a randomized design. Benefits, Harms, and Costs: The possible consequences of false-positive and -negative tests were considered in evaluating a preference for one of two tests providing similar information. Cost alone was not a determining factor. Recommendations: The attached guidelines and text summarize the updated recommendations of the ASCO breast cancer expert panel. Data are sufficient to recommend monthly breast self-examination, annual mammography of the preserved and contralateral breast, and a careful history and physical examination every 3 to 6 months for 3 years, then every 6 to 12 months for 2 years, then annually. Data are not sufficient to recommend routine bone scans, chest radiographs, hematologic blood counts, tumor markers (carcinoembryonic antigen, cancer antigen [CA] 15-5, and CA 27.29), liver ultrasonograms, or computed tomography scans. Validation: The recommendations of the breast cancer expert panel were evaluated and supported by the ASCO Health Services Research Committee reviewers and the ASCO Board of Directors. Sponsor: American Society of Clinical Oncology.

Original languageEnglish (US)
Pages (from-to)1080-1082
Number of pages3
JournalJournal of Clinical Oncology
Volume17
Issue number3
StatePublished - Mar 1999
Externally publishedYes

Fingerprint

Medical Oncology
Guidelines
Breast Neoplasms
Cost-Benefit Analysis
Breast Self-Examination
Antigens
Health Services Research
Carcinoembryonic Antigen
Differentiation Antigens
Neoplasm Antigens
Mammography
Tumor Biomarkers
Practice Guidelines
Disease-Free Survival
Physical Examination
Publications
Neoplasms
Breast
Thorax
Retrospective Studies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Smith, T. J., Davidson, N. E., Schapira, D. V., Grunfeld, E., Muss, H. B., Vogel, V. G., & Somerfield, M. R. (1999). American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. Journal of Clinical Oncology, 17(3), 1080-1082.

American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. / Smith, Thomas J; Davidson, Nancy E.; Schapira, David V.; Grunfeld, Eva; Muss, Hyman B.; Vogel, Victor G.; Somerfield, Mark R.

In: Journal of Clinical Oncology, Vol. 17, No. 3, 03.1999, p. 1080-1082.

Research output: Contribution to journalArticle

Smith, TJ, Davidson, NE, Schapira, DV, Grunfeld, E, Muss, HB, Vogel, VG & Somerfield, MR 1999, 'American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines', Journal of Clinical Oncology, vol. 17, no. 3, pp. 1080-1082.
Smith TJ, Davidson NE, Schapira DV, Grunfeld E, Muss HB, Vogel VG et al. American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. Journal of Clinical Oncology. 1999 Mar;17(3):1080-1082.
Smith, Thomas J ; Davidson, Nancy E. ; Schapira, David V. ; Grunfeld, Eva ; Muss, Hyman B. ; Vogel, Victor G. ; Somerfield, Mark R. / American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. In: Journal of Clinical Oncology. 1999 ; Vol. 17, No. 3. pp. 1080-1082.
@article{9a47e525790e46a484ab2fba18f26dd4,
title = "American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines",
abstract = "Objective: To determine an effective, evidence-based, postoperative surveillance strategy for the detection and treatment of recurrent breast cancer. Tests are recommended only if they have an impact on the outcomes specified by American Society of Clinical Oncology (ASCO) for clinical practice guidelines. Potential Interventlon: All tests described in the literature for postoperative monitoring were considered. In addition, the data were critically evaluated to determine the optimal frequency of monitoring. Outcome: Outcomes of interest include overall and disease-free survival, quality of life, toxicity reduction, and secondarily cost- effectiveness. Evidence: A search was performed to determine all relevant articles published over the past 20 years on the efficacy of surveillance testing for breast cancer recurrence. These publications comprised both retrospective and prospective studies. Values: Levels of evidence and guideline grades were rated by a standard process. More weight was given to studies that tested a hypothesis directly relating testing to one of the primary outcomes in a randomized design. Benefits, Harms, and Costs: The possible consequences of false-positive and -negative tests were considered in evaluating a preference for one of two tests providing similar information. Cost alone was not a determining factor. Recommendations: The attached guidelines and text summarize the updated recommendations of the ASCO breast cancer expert panel. Data are sufficient to recommend monthly breast self-examination, annual mammography of the preserved and contralateral breast, and a careful history and physical examination every 3 to 6 months for 3 years, then every 6 to 12 months for 2 years, then annually. Data are not sufficient to recommend routine bone scans, chest radiographs, hematologic blood counts, tumor markers (carcinoembryonic antigen, cancer antigen [CA] 15-5, and CA 27.29), liver ultrasonograms, or computed tomography scans. Validation: The recommendations of the breast cancer expert panel were evaluated and supported by the ASCO Health Services Research Committee reviewers and the ASCO Board of Directors. Sponsor: American Society of Clinical Oncology.",
author = "Smith, {Thomas J} and Davidson, {Nancy E.} and Schapira, {David V.} and Eva Grunfeld and Muss, {Hyman B.} and Vogel, {Victor G.} and Somerfield, {Mark R.}",
year = "1999",
month = "3",
language = "English (US)",
volume = "17",
pages = "1080--1082",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "3",

}

TY - JOUR

T1 - American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines

AU - Smith, Thomas J

AU - Davidson, Nancy E.

AU - Schapira, David V.

AU - Grunfeld, Eva

AU - Muss, Hyman B.

AU - Vogel, Victor G.

AU - Somerfield, Mark R.

PY - 1999/3

Y1 - 1999/3

N2 - Objective: To determine an effective, evidence-based, postoperative surveillance strategy for the detection and treatment of recurrent breast cancer. Tests are recommended only if they have an impact on the outcomes specified by American Society of Clinical Oncology (ASCO) for clinical practice guidelines. Potential Interventlon: All tests described in the literature for postoperative monitoring were considered. In addition, the data were critically evaluated to determine the optimal frequency of monitoring. Outcome: Outcomes of interest include overall and disease-free survival, quality of life, toxicity reduction, and secondarily cost- effectiveness. Evidence: A search was performed to determine all relevant articles published over the past 20 years on the efficacy of surveillance testing for breast cancer recurrence. These publications comprised both retrospective and prospective studies. Values: Levels of evidence and guideline grades were rated by a standard process. More weight was given to studies that tested a hypothesis directly relating testing to one of the primary outcomes in a randomized design. Benefits, Harms, and Costs: The possible consequences of false-positive and -negative tests were considered in evaluating a preference for one of two tests providing similar information. Cost alone was not a determining factor. Recommendations: The attached guidelines and text summarize the updated recommendations of the ASCO breast cancer expert panel. Data are sufficient to recommend monthly breast self-examination, annual mammography of the preserved and contralateral breast, and a careful history and physical examination every 3 to 6 months for 3 years, then every 6 to 12 months for 2 years, then annually. Data are not sufficient to recommend routine bone scans, chest radiographs, hematologic blood counts, tumor markers (carcinoembryonic antigen, cancer antigen [CA] 15-5, and CA 27.29), liver ultrasonograms, or computed tomography scans. Validation: The recommendations of the breast cancer expert panel were evaluated and supported by the ASCO Health Services Research Committee reviewers and the ASCO Board of Directors. Sponsor: American Society of Clinical Oncology.

AB - Objective: To determine an effective, evidence-based, postoperative surveillance strategy for the detection and treatment of recurrent breast cancer. Tests are recommended only if they have an impact on the outcomes specified by American Society of Clinical Oncology (ASCO) for clinical practice guidelines. Potential Interventlon: All tests described in the literature for postoperative monitoring were considered. In addition, the data were critically evaluated to determine the optimal frequency of monitoring. Outcome: Outcomes of interest include overall and disease-free survival, quality of life, toxicity reduction, and secondarily cost- effectiveness. Evidence: A search was performed to determine all relevant articles published over the past 20 years on the efficacy of surveillance testing for breast cancer recurrence. These publications comprised both retrospective and prospective studies. Values: Levels of evidence and guideline grades were rated by a standard process. More weight was given to studies that tested a hypothesis directly relating testing to one of the primary outcomes in a randomized design. Benefits, Harms, and Costs: The possible consequences of false-positive and -negative tests were considered in evaluating a preference for one of two tests providing similar information. Cost alone was not a determining factor. Recommendations: The attached guidelines and text summarize the updated recommendations of the ASCO breast cancer expert panel. Data are sufficient to recommend monthly breast self-examination, annual mammography of the preserved and contralateral breast, and a careful history and physical examination every 3 to 6 months for 3 years, then every 6 to 12 months for 2 years, then annually. Data are not sufficient to recommend routine bone scans, chest radiographs, hematologic blood counts, tumor markers (carcinoembryonic antigen, cancer antigen [CA] 15-5, and CA 27.29), liver ultrasonograms, or computed tomography scans. Validation: The recommendations of the breast cancer expert panel were evaluated and supported by the ASCO Health Services Research Committee reviewers and the ASCO Board of Directors. Sponsor: American Society of Clinical Oncology.

UR - http://www.scopus.com/inward/record.url?scp=0033011071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033011071&partnerID=8YFLogxK

M3 - Article

C2 - 10071303

AN - SCOPUS:0033011071

VL - 17

SP - 1080

EP - 1082

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 3

ER -